Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Susan M. Buttler"'
Autor:
Susan M. Buttler, Darryl J. Sleep, Anne C. Goldberg, James C. Stolzenbach, Carolyn M. Setze, Peter B. Jones, Aditya Lele, Carl J. Pepine, Maureen T. Kelly, Michael H. Davidson
Publikováno v:
Journal of Clinical Lipidology. 3:125-137
Patients with mixed dyslipidemia often require combination therapy to manage multiple lipid abnormalities.To evaluate fenofibric acid in combination with a statin across three studies of patients with mixed dyslipidemia.As prospectively planned, data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3213e2f20efe827840abad19cf426cb
https://doi.org/10.1016/j.jacl.2009.02.007
https://doi.org/10.1016/j.jacl.2009.02.007
Autor:
Anne C. Goldberg, Harold E. Bays, Carolyn M. Setze, Susan M. Buttler, Darryl J. Sleep, Maureen T. Kelly, Christie M. Ballantyne, James C. Stolzenbach
Publikováno v:
The American Journal of Cardiology. 103:515-522
In patients with mixed dyslipidemia characterized by increased triglycerides (TG), decreased high-density lipoprotein (HDL) cholesterol, and increased low-density lipoprotein (LDL) cholesterol, monotherapy with lipid-altering drugs often fails to ach
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b04056c064e10780115af7c7cf95941
https://doi.org/10.1016/j.amjcard.2008.10.025
https://doi.org/10.1016/j.amjcard.2008.10.025
Publikováno v:
Urology. 56:130-135
Objectives. A sublingual (SL) formulation of apomorphine has been developed and found effective in penile erectile dysfunction (ED). This study assessed the efficacy and safety of several doses of apomorphine SL in a dose-optimization schedule compar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::826d3cecedd03344baf7238a953b6daf
https://doi.org/10.1016/s0090-4295(00)00575-6
https://doi.org/10.1016/s0090-4295(00)00575-6
Autor:
Harold E. Bays, Peter H. Jones, Syed M. Mohiuddin, Maureen T. Kelly, Hsiaoming Sun, Carolyn M. Setze, Susan M. Buttler, Darryl J. Sleep, James C. Stolzenbach
Publikováno v:
Circulation. 118
Background: The efficacy and safety of ABT-335 + statin combination therapy was demonstrated in three 12-week, controlled studies of patients with mixed dyslipidemia randomized to ABT-335 (135mg) + low or moderate dose rosuvastatin (R), simvastatin (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::249521e4fe43567479876f0954c74925
https://doi.org/10.1161/circ.118.suppl_18.s_476-c
https://doi.org/10.1161/circ.118.suppl_18.s_476-c
Autor:
Susan M. Buttler, Darryl J. Sleep, James C. Stolzenbach, Peter B. Jones, Hsiaoming Sun, Harold E. Bays, Carolyn M. Setze, Syed M. Mohiuddin, Maureen T. Kelly
Publikováno v:
Journal of clinical lipidology. 2(6)
Background Co-administration of a fibrate and statin is an effective treatment option for patients with multiple lipid abnormalities, yet adequate long-term safety and efficacy data are lacking. Objective To evaluate the long-term safety and efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0f7c7a2121d361a568fd227fb3da99b
https://pubmed.ncbi.nlm.nih.gov/21291776
https://pubmed.ncbi.nlm.nih.gov/21291776
Autor:
Harold E. Bays, Michael H. Davidson, Susan M. Buttler, Peter B. Jones, Darryl J. Sleep, Carolyn M. Setze, James C. Stolzenbach, Maureen T. Kelly
Publikováno v:
Clinical drug investigation. 28(10)
Atherogenic lipid parameters in patients with mixed dyslipidaemia have been demonstrated to increase atherosclerotic coronary heart disease (CHD) risk. Clinical studies have shown that HMG-CoA reductase inhibitor (statin) and fibric acid derivative (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93fde313984719f634705332f7f2a1ea
https://pubmed.ncbi.nlm.nih.gov/18783301
https://pubmed.ncbi.nlm.nih.gov/18783301
Autor:
Maureen T. Kelly, Moti L. Kashyap, Susan M. Buttler, Michael H. Davidson, Carolyn M. Setze, James C. Stolzenbach, Darryl J. Sleep, Peter B. Jones
Publikováno v:
Atherosclerosis. 204(1)
To evaluate a new formulation of fenofibric acid (ABT-335) co-administered with 2 doses of rosuvastatin in patients with mixed dyslipidemia.In a phase 3, multicenter, randomized, double-blind, active-controlled study, a total of 1445 patients with LD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f331197fc0377ab1539d4cae01104419
https://pubmed.ncbi.nlm.nih.gov/18996523
https://pubmed.ncbi.nlm.nih.gov/18996523
Autor:
James C. Stolzenbach, Carolyn M. Setze, Susan M. Buttler, Darryl J. Sleep, Carl J. Pepine, Syed M. Mohiuddin, Maureen T. Kelly
Publikováno v:
American heart journal. 157(1)
Patients with mixed dyslipidemia often require combination therapy to effectively control lipid abnormalities. This study compared the effects of combination therapy with ABT-335 (a new formulation of fenofibric acid) and simvastatin to ABT-335 and s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daf4987258a985ddf17ef85b576b88fd
https://pubmed.ncbi.nlm.nih.gov/19081418
https://pubmed.ncbi.nlm.nih.gov/19081418
Publikováno v:
The American journal of cardiology. 88(7)
Sublingual (SL) apomorphine (2 to 6 mg) has been shown to be effective for treatment of male erectile dysfunction. Many patients with erectile dysfunction are also being treated for systemic hypertension and/or cardiovascular disease. In a double-bli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd97d665fe21e0c84fc6ca7fff1c447a
https://pubmed.ncbi.nlm.nih.gov/11589843
https://pubmed.ncbi.nlm.nih.gov/11589843